En Es
Categories

Illumina

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological functions. The company also provides sequencing and array-based solutions for genetic analysis, as well as genotyping, NIPT and whole-genome sequencing services for government laboratories, hospitals, an ...
Products Covid-19Summary
Close

Covid-19 Illumina

Clinical Laboratory

SARS-CoV-2 (COVID-19) Test
Illumina COVIDSeq Test

The Illumina COVIDSeq Test is the first NGS test approved for use under the US Food and Drug Administration’s Emergency Use Authorization (EUA). This amplicon-based NGS test includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs from patients with signs and symptoms of infection who are suspected of COVID-19. The test can be run on the Illumina NovaSeq 6000 Sequencing System, NextSeq 500 Sequencing System, NextSeq 550 Sequencing System, or NextSeq 550Dx Instrument.
More details
Close

About Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological functions. The company also provides sequencing and array-based solutions for genetic analysis, as well as genotyping, NIPT and whole-genome sequencing services for government laboratories, hospitals, and reference laboratories, among others.

Recently updated

NGS System
iSeq 100 System

The iSeq 100 System is a low cost, RUO only benchtop next generation sequencer that is one cubic feet and includes a mounted 10 inch screen. Leveraging the speed and affordability of complementary metal-oxide-semiconductor (CMOS) technology and the accuracy of sequencing by synthesis (SBS) chemistry, it enables virtually any lab to acquire powerful next-generation sequencing (NGS) technology. The iSeq 100 System is ideal for small whole-genome sequencing (eg, bacteria, viruses, plasmids), targeted sequencing of a set of genes or gene regions, gene expression analysis, or 16S metagenomics.
More details

NGS System
NextSeq 2000

The NextSeq 2000 next-generation sequencing (NGS) system offers innovative design features, advanced chemistry, simplified bioinformatics, and an intuitive workflow that enable the widest range of applications on a benchtop sequencing system. It uses Illumina’s patterned flow cells, resulting in a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.
More details

SARS-CoV-2 (COVID-19) Test
Illumina COVIDSeq Test

The Illumina COVIDSeq Test is the first NGS test approved for use under the US Food and Drug Administration’s Emergency Use Authorization (EUA). This amplicon-based NGS test includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs from patients with signs and symptoms of infection who are suspected of COVID-19. The test can be run on the Illumina NovaSeq 6000 Sequencing System, NextSeq 500 Sequencing System, NextSeq 550 Sequencing System, or NextSeq 550Dx Instrument.
More details

Clinical Laboratory

NGS System
iSeq 100 System

The iSeq 100 System is a low cost, RUO only benchtop next generation sequencer that is one cubic feet and includes a mounted 10 inch screen. Leveraging the speed and affordability of complementary metal-oxide-semiconductor (CMOS) technology and the accuracy of sequencing by synthesis (SBS) chemistry, it enables virtually any lab to acquire powerful next-generation sequencing (NGS) technology. The iSeq 100 System is ideal for small whole-genome sequencing (eg, bacteria, viruses, plasmids), targeted sequencing of a set of genes or gene regions, gene expression analysis, or 16S metagenomics.
More details

NGS System
NextSeq 2000

The NextSeq 2000 next-generation sequencing (NGS) system offers innovative design features, advanced chemistry, simplified bioinformatics, and an intuitive workflow that enable the widest range of applications on a benchtop sequencing system. It uses Illumina’s patterned flow cells, resulting in a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.
More details

SARS-CoV-2 (COVID-19) Test
Illumina COVIDSeq Test

The Illumina COVIDSeq Test is the first NGS test approved for use under the US Food and Drug Administration’s Emergency Use Authorization (EUA). This amplicon-based NGS test includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs from patients with signs and symptoms of infection who are suspected of COVID-19. The test can be run on the Illumina NovaSeq 6000 Sequencing System, NextSeq 500 Sequencing System, NextSeq 550 Sequencing System, or NextSeq 550Dx Instrument.
More details

NGS System
NextSeq 550Dx

The NextSeq 550Dx is a FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system with dual boot functionality, and includes a diagnostic mode (Dx mode) and a research mode, providing the flexibility to perform both clinical research and develop a range of IVD assays on a single instrument. It offers a validated high-throughput platform for large clinical laboratories, and fully-integrated onboard analysis software with modular software architecture to support current and future assays.
More details

NGS Test
MiSeqDx Cystic Fibrosis 139-Variant Assay

The MiSeqDx Cystic Fibrosis 139-Variant Assay is an FDA-cleared in vitro diagnostic (IVD) next-generation sequencing test designed to detect 139 CFTR variants. It provides a fully integrated molecular CF testing solution on the MiSeqDx instrument and includes all index primers and reagents needed for library preparation, sample multiplexing, and sequencing in a single kit.
More details

Reagents
MiSeqDx Universal Kit

The MiSeqDx Universal Kit is a validated, FDA-cleared amplicon sequencing solution that enables clinical laboratories to develop their own next-generation sequencing (NGS) assays for use on the FDA-cleared MiSeqDx instrument. It allows molecular diagnostics labs to develop assays using oligonucleotide probes designed on their own and provides a quick and easy to perform automated workflow to potentially minimize human error.
More details

Clinical NGS System
MiSeqDx System

The MiSeqDx System is the first FDA-cleared next-generation sequencing (NGS) platform for in vitro diagnostic (IVD) testing that provides accurate, reliable data for screening and diagnostic testing, including assays for cystic fibrosis testing. Designed specifically for clinical laboratories, it delivers a broad range of sequencing applications and provides an easy-to-use, automated workflow for obtaining comprehensive and reliable DNA sequencing results.
More details
Copyright © 2000-2020 TradeMed.com. All rights reserved. | Terms And Conditions